Jama M. Darling

Suggest Changes
Learn More
BACKGROUND Protease inhibitors have improved treatment of infection with hepatitis C virus (HCV), but dosing, a low barrier to resistance, drug interactions, and side-effects restrict their use. We(More)
Chronic hepatitis C virus (HCV) infection affects approximately 1.3% of the general U.S. population and 5–10% of veterans who use Department of Veterans Affairs medical services. Chronic HCV is(More)
We report the findings of an early access program providing treatment for chronic hepatitis C virus infection (any genotype) with daclatasvir and sofosbuvir with/without ribavirin to patients with(More)